Evidence map›Paper›PMID 38985369›Full record

ArticleJournal of physiology and biochemistry2024

Modulation of miR-155-5p signalling via 5-ASA for the prevention of high microsatellite instability: an in vitro study using human epithelial cell lines.

Monika Adamowicz, Joanna Abramczyk, Ewa Kilanczyk, Piotr Milkiewicz, Alicja Łaba, Malgorzata Milkiewicz, Agnieszka Kempinska-Podhorodecka

Abstract read
In one paragraph

Article in Journal of physiology and biochemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Monika AdamowiczDepartment of Medical Biology, Pomeranian Medical University in Szczecin, Szczecin, 70-111, Poland.
Joanna AbramczykDepartment of Medical Biology, Pomeranian Medical University in Szczecin, Szczecin, 70-111, Poland.
Ewa KilanczykDepartment of Medical Biology, Pomeranian Medical University in Szczecin, Szczecin, 70-111, Poland.
Piotr MilkiewiczLiver and Internal Medicine Unit, Medical University of Warsaw, Warszawa, Poland.
Alicja ŁabaDepartment of Medical Biology, Pomeranian Medical University in Szczecin, Szczecin, 70-111, Poland.
Malgorzata MilkiewiczDepartment of Medical Biology, Pomeranian Medical University in Szczecin, Szczecin, 70-111, Poland.
Agnieszka Kempinska-PodhorodeckaDepartment of Medical Biology, Pomeranian Medical University in Szczecin, Szczecin, 70-111, Poland. agnieszka.kempinska.podhorodecka@pum.edu.pl.

Funding

National Science Centre in Poland 2020/39/O/NZ4/01732
6 · The paper itself

Abstract

5-aminosalicylic acid (5-ASA) is a first-line treatment for maintaining colitis remission. It is a highly effective, safe, and well-tolerated drug with anti-inflammatory and chemo-preventive properties. While patients with primary sclerosing cholangitis (PSC) with concomitant ulcerative colitis are treated with 5-ASA, the molecular mechanisms underlying the drug's chemo-preventive effects are not entirely understood. We previously reported that bile acids and lipopolysaccharide-induced miR-155 expression was associated with downregulating mismatch repair (MMR) proteins in CACO-2 cell lines. Therefore, in this investigation, a set of in vitro functional studies was performed to show the possible mechanisms behind the epigenetic relationship between miR-155 and 5-ASA's prevention of high microsatellite instability (MSI-H). In transient transfection with miR-155Mimic, which behaves like endogenous miRNA, we confirmed the relationships between miR-155 and its target MMR in three human intestinal epithelial cell lines: CACO-2, NCM460D and HT-29. We have shown, for the first time, that 5-ASA modulates MLH1, MSH2, MSH6 in miR-155 transfected cells. These findings underline that chemoprotective 5-ASA therapy can effectively attenuate the expression of miR-155 and potentially prevent a development of MSI-H in a subset of colorectal cancers associated with PSC.

Indexed as

MesalamineMicroRNAsMicrosatellite InstabilityAnti-Inflammatory Agents, Non-SteroidalCaco-2 CellsDNA-Binding ProteinsDNA Mismatch RepairEpithelial CellsHT29 CellsHumansMutL Protein Homolog 1MutS Homolog 2 ProteinSignal TransductionAnti-Inflammatory Agents, Non-SteroidalDNA-Binding ProteinsMesalamineMicroRNAsMIRN155 microRNA, humanMLH1 protein, humanMSH2 protein, humanMutL Protein Homolog 1MutS Homolog 2 ProteinAminosalicylic acidsmiR-155Mismatch repair genesPrimary sclerosing cholangitis

Identifiers

PMID38985369
PMCPMC11502576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.